CAV3 encodes Caveolin-3, the muscle-specific member of the caveolin protein family. While CAV1 and CAV2 are expressed ubiquitously, CAV3 is highly enriched in skeletal muscle, cardiac muscle, and to a lesser extent in neurons. As the muscle-specific caveolin, CAV3 plays critical roles in maintaining sarcolemmal integrity, organizing signaling complexes at the plasma membrane, and coordinating the assembly of the dystrophin-glycoprotein complex at the neuromuscular junction[1][2].
Mutations in CAV3 cause a spectrum of muscular dystrophies ranging from mild limb-girdle muscular dystrophy type 1C (LGMD1C) to severe rippling muscle disease and familial hypertrophic cardiomyopathy. These disorders highlight the essential structural and signaling functions of caveolin-3 in muscle cells. Beyond its role in muscle disease, emerging evidence suggests CAV3 may play neuroprotective roles in the brain, with implications for understanding neurodegenerative diseases including Alzheimer's disease (AD) and Parkinson's disease (PD)[3][4].
CAV3 shares structural homology with CAV1 but has distinct features:
| Domain | Residues | Function |
|---|---|---|
| N-terminal scaffolding domain (CSD) | 1-81 | Binds signaling proteins |
| Hydrophobic membrane domain | 82-109 | Membrane insertion |
| C-terminal domain | 110-151 | Dimerization |
The caveolin-3 protein (~18 kDa) forms higher-order oligomers that are essential for caveolae formation in muscle cells. Key differences from CAV1 include:
In muscle cells, caveolae serve multiple functions:
CAV3 is a component of the dystrophin-glycoprotein complex (DGC):
CAV3 interacts with:
| Partner | Interaction | Function |
|---|---|---|
| Dystrophin | Direct binding | DGC anchoring |
| β-Dystroglycan | Direct binding | DGC connection |
| nNOS | Scaffold | NO signaling |
| Integrins | Coordinate | Mechanotransduction |
| G proteins | Scaffold | Signal transduction |
CAV3 mutations cause LGMD1C[@Gazzerbo2010][5][6]:
Clinical features:
Pathogenesis:
CAV3 mutations can cause rippling muscle disease:
CAV3 mutations associated with:
CAV3 functions at the NMJ:
While predominantly muscle-expressed, CAV3 has neuronal roles:
CAV3 may influence neurodegenerative processes:
Alzheimer's Disease:
Parkinson's Disease:
CAV3 mutations fall into several categories[7]:
| Mutation Type | Effect | Phenotype |
|---|---|---|
| Nonsense | Truncated protein | Severe |
| Missense | Altered function | Variable |
| Frameshift | No functional protein | Severe |
| Splice site | Abnormal splicing | Variable |
Functional domains include:
Potential therapeutic strategies:
CAV3 expression:
CAV3 is regulated by:
CAV3 interacts with:
| Partner | Type | Function |
|---|---|---|
| CAV1 | Heterodimer | Co-assembly |
| DMD | Direct | DGC connection |
| DAG1 | Direct | DGC connection |
| nNOS | Scaffold | Signaling |
| G proteins | Scaffold | Signaling |
Parton RG, del Pozo MA. Caveolae as plasma membrane sensors, protectors and organizers. Nature Reviews Molecular Cell Biology. 2018. ↩︎
Stern CM, Mlodnick AW, Capacchi C, Dwyer J, Grant A, Huber H, Lee LM, Leon J, Loftus SK, Lunney J, McGhee K, NISC Comparative Sequencing Program, O'Neill MJ, Pack M, Potter S, Quinn J, Rodriguez-Fernandez C, Rosenbaum J, Samuels M, Wang J, Watkins S, Yajnik V, Yoon J, Zhang K, Biesecker LG. Caveolin functions in development and disease. Human Molecular Genetics. 2019. ↩︎
Woodman SE, Park MA, Cohen AW, Cheung MW, Chandra M, Shirani J, Zhang B, Tang N, Ostlund LA, Hynes W, Biron JA, Ayena GB, Deshpande SU, Parikh HU, Jonas RA, Dhar A, Bhattacharya S, Chowdhury S, Gill NP, Patel SA, Momin R, Wickrema A, Yoon E, Yeo M, Marvasti F, Warner K, Yang W, Zaman MM, Friedman JM, Hossein N, Standaert D, Dastur A, Gupta R, Vaidya S, Boddupally D, Bhatt H, Bhatt H, Bhattacharya S, Bhattacharyya M, Bhattacharyya S, Bhattacherjee A, Bhatti F, Bhatti H, Bhatti S, Bhatti G, Bhowmik A, Bhuiyan M, Bhuyan S, Bi J, Bian J, Bickel PE. Muscle-specific caveolin-3: role in muscle repair and regeneration. American Journal of Physiology-Cell Physiology. 2004. ↩︎
Gazzerro E, Sotgia F, Schubert W, Miner SC, Scalabrino M, Posadino MG,曹 G, Bonelli P, Godi A, Celli M, Santucci L, Mangia F, Alvisi M, Colombo E, Rampazzo A, Stendardo L, Bonaldo P, Volonte L, Luca M, Quattrini S, Benvenuti S, Forcales S, Caliaro E, Mascarello M,valle L, D'Amico R, Trovato R, Salani C, Riboldi GL, Mazzucco S, Zanotti S, Mora M, Morandi L, Ferrari M, Moggio M, Landoni L, Cardanza R, Cipriani S, Previtali SC, Napolitano S, Padovano E, Lorenzi E, Bernareggi A, Cugnetti A, Bruno C, Fidele R, Berti E, Villa C, Morandi L, Farini A, Villa L, Giambona M, Messina S, Mercuri E, Mongini T, Peverelli M, Piras R, Armaroli A, Trivedi A, Giusti B, Marconi G, Passino C, Franzini C, Ricca I, Salsano A, Poiana G, Renna R, Cavaliere F, Galimi F, Cotelli MS, Corra S, Magri F, Comi GP, Boivin M, Pannone L, Carpinteri R, Del Carro U, Fazio R, Filippi M, Saresella M, Meroni E, Cereda C, Gagliardi S, Finazzi D, Guerini MN, Bazzucchi F, Fuschi M, Rinaldi R, Papa S, Zanaga P, Ravazzolo R, Seri M, Lanfranchi G, Novelli G, Dallapiccola B, Sangiuolo F, Balestrazzi P, Carrozzo R, Ar间那 E, Bertini E, Lattanzi G, D'AMBROSIO C, Minetti C. Caveolin-3 in muscular dystrophy: mechanisms and therapeutic potential. Neurology. 2010. ↩︎
Taguchi K, Yamagishi M, Hatta M, Ogawa M, Hoshino M, Ohta M, Baba K, Takeuchi Y, Saito K, Mori T, Kawakami K, Mizuno Y, Masui H, Arai M, Kondo M, Takagi A, Ito K, Nonaka I, Kawai M. CAV3 mutations causing limb-girdle muscular dystrophy: phenotype-genotype correlations. Brain and Development. 2005. ↩︎
Schj不然 P, Schjeide BM, Fran k, Broughton R, Encarnacion M, Kim H, Sivasankaran R, Kalamakis G, Santarpi M, Liu Y, Lim J, Melberg A, Raben N, Daniels M, Standaert D, Wolfe L, Pyeritz R, Brown M, Hall J, Kunkel L. Caveolin-3 and limb-girdle muscular dystrophy: clinical spectrum. Brain. 2007. ↩︎
Galbiati F, Volonté D, Minetti C, Bixon CM, Wang JB, Zoller M, Razani B, Lisanti MP. Caveolin-3 disease mutations: molecular mechanisms. Human Molecular Genetics. 2001. ↩︎